Drug Trial Radar · NCT07355205
First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer
Last checked: Nov 20, 2026Latest source record: Jul 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
26
Planned (sponsor's estimate)
Start
Jul 7, 2026
Primary completion
Jul 31, 2032
Study completion Jul 31, 2032
Sponsor
- Lead sponsor
- Washington University School of MedicineAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- ImmunityBio, Inc.; The Foundation for Barnes-Jewish Hospital
- First posted
- Jan 21, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a single center, phase Ib/II study combining an anti-PD-1 antibody and an anti-CTLA-4 antibody with IL-15. It is testing the hypothesis that the addition of nogapendekin alfa inbakicept to nivolumab and ipilimumab will augment the clinical activity of those two drugs.
Conditions
- Non-small Cell Lung Cancer Stage IV
- Non-small Cell Lung Cancer Recurrent
Interventions
IpilimumabDrug
Ipilimumab will be given intravenously at a dose of 1mg/kg.
NivolumabDrug
Nivolumab will be given intravenously at a dose of 360mg.
Nogapendekin alfa inbakiceptDrug
Nogapendekin alfa inbakicept will be given subcutaneously at the assigned dose level.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survival (PFS) (Phase Ib acceptable dose participants and Phase II participants)Time frame: Start of treatment through 2 years after end of treatment (up to 4 years)
- Incidence of dose-limiting toxicities (DLTs) (Phase Ib participants)Time frame: From start of treatment through completion of cycle 1 (each cycle is 42 days)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Washington University School of Medicine
St Louis, Missouri · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.